(Mostly) Asia M&A: October 2019 Roundup
For the month of October, 17 new deals were discussed on Smartkarma with an overall announced deal size of ~US$34bn. Clicking on the company...
535 Views
(Mostly) Asia M&A: September 2019 Roundup
For the month of September, 12 new deals were discussed on Smartkarma with an overall announced deal size of ~US$250bn, aided by the mega-merger of...
592 Views
(Mostly) Asia M&A: August 2019 Roundup
For the month of August, 16 new deals were discussed on Smartkarma with an overall announced deal size of ~US$23bn. Clicking on the company name in...
557 Views
MergerTalk: Pfizer/Mylan -Don't Overdose on the Sector, but Mylan Over Teva Pair Trade Is Still On
The recently announced Reverse Morris Trust transaction involving the merger of Pfizer's (PFE US) off-patent business (Upjohn) with Mylan (MYL US)...
507 Views
Biosimilar Battlefield: The Remsima/Inflectra Warning
2019 marks an inflection point for Korean biosimilar companies Celltrion Healthcare (091990 KS), Celltrion Inc (068270 KS), and Samsung Biologics...
696 Views